中华病理学杂志
中華病理學雜誌
중화병이학잡지
Chinese Journal of Pathology
2011年
8期
528-531
,共4页
霍颖颖%潘毅%管冰心%房爱菊%孙保存%周庚寅%FU Kai%孟斌
霍穎穎%潘毅%管冰心%房愛菊%孫保存%週庚寅%FU Kai%孟斌
곽영영%반의%관빙심%방애국%손보존%주경인%FU Kai%맹빈
淋巴瘤,滤泡型%微阵列分析%免疫组织化学
淋巴瘤,濾泡型%微陣列分析%免疫組織化學
림파류,려포형%미진렬분석%면역조직화학
Lymphoma,follicular%Microarray analysis%Immunohistochemistry
目的 检测MUM-1/IRF4在滤泡性淋巴瘤中的表达,并探讨其在滤泡性淋巴瘤中表达的生物学意义.方法 应用组织芯片和免疫组织化学SP法检测98例滤泡性淋巴瘤中MUM-1/IRF4及CD10、bcl-6、bcl-2、Ki-67的表达,对MUM-1/IRF4在不同级别滤泡性淋巴瘤中的表达及与其他几个相关蛋白标志物表达的关系进行统计学分析.结果 (1)MUM-1/IRF4在滤泡性淋巴瘤中的表达率为39.8%(39/98),CD10为62.2%(61/98),bcl-6为80.6%(79/98),bcl-2为87.8%(86/98),Ki-67高表达(≥25%)的阳性率为50.0%(49/98);(2)MUM-1/IRF4主要在高级别滤泡性淋巴瘤中表达,与分级(r=0.628,P=0.000)和Ki-67(r=0.473,P=0.000)的表达呈正相关;(3)MUM-1/IRF4与CD10的表达呈负相关(r=-0.597,P=0.000),与bcl-6和bcl-2的表达无相关性.结论 MUM-1/IRF4在高级别滤泡性淋巴瘤中显著性高表达,MUM-1/IRF4阳性病例肿瘤细胞增殖活性高,提示其进展快,预后差,MUM-1/IRF4强阳性有助于高级别滤泡性淋巴瘤的诊断.
目的 檢測MUM-1/IRF4在濾泡性淋巴瘤中的錶達,併探討其在濾泡性淋巴瘤中錶達的生物學意義.方法 應用組織芯片和免疫組織化學SP法檢測98例濾泡性淋巴瘤中MUM-1/IRF4及CD10、bcl-6、bcl-2、Ki-67的錶達,對MUM-1/IRF4在不同級彆濾泡性淋巴瘤中的錶達及與其他幾箇相關蛋白標誌物錶達的關繫進行統計學分析.結果 (1)MUM-1/IRF4在濾泡性淋巴瘤中的錶達率為39.8%(39/98),CD10為62.2%(61/98),bcl-6為80.6%(79/98),bcl-2為87.8%(86/98),Ki-67高錶達(≥25%)的暘性率為50.0%(49/98);(2)MUM-1/IRF4主要在高級彆濾泡性淋巴瘤中錶達,與分級(r=0.628,P=0.000)和Ki-67(r=0.473,P=0.000)的錶達呈正相關;(3)MUM-1/IRF4與CD10的錶達呈負相關(r=-0.597,P=0.000),與bcl-6和bcl-2的錶達無相關性.結論 MUM-1/IRF4在高級彆濾泡性淋巴瘤中顯著性高錶達,MUM-1/IRF4暘性病例腫瘤細胞增殖活性高,提示其進展快,預後差,MUM-1/IRF4彊暘性有助于高級彆濾泡性淋巴瘤的診斷.
목적 검측MUM-1/IRF4재려포성림파류중적표체,병탐토기재려포성림파류중표체적생물학의의.방법 응용조직심편화면역조직화학SP법검측98례려포성림파류중MUM-1/IRF4급CD10、bcl-6、bcl-2、Ki-67적표체,대MUM-1/IRF4재불동급별려포성림파류중적표체급여기타궤개상관단백표지물표체적관계진행통계학분석.결과 (1)MUM-1/IRF4재려포성림파류중적표체솔위39.8%(39/98),CD10위62.2%(61/98),bcl-6위80.6%(79/98),bcl-2위87.8%(86/98),Ki-67고표체(≥25%)적양성솔위50.0%(49/98);(2)MUM-1/IRF4주요재고급별려포성림파류중표체,여분급(r=0.628,P=0.000)화Ki-67(r=0.473,P=0.000)적표체정정상관;(3)MUM-1/IRF4여CD10적표체정부상관(r=-0.597,P=0.000),여bcl-6화bcl-2적표체무상관성.결론 MUM-1/IRF4재고급별려포성림파류중현저성고표체,MUM-1/IRF4양성병례종류세포증식활성고,제시기진전쾌,예후차,MUM-1/IRF4강양성유조우고급별려포성림파류적진단.
Objective To study the expression of MUM-1/IRF4 and its significance in follicular lymphoma. Methods Ninety-eight cases of follicular lymphoma were enrolled into the study. They were graded according to the 2008 WHO criteria. The expression of MUM-1/IRF4 protein and other markers (CD10, bcl-6, bcl-2 and Ki-67) was studied using tissue microarray and immunohistochemistry. Results Amongst the 98 cases studied, there were 24 grade 1 cases, 30 grade 2 cases, 26 grade 3A cases and 18 were grade 3B cases. The rates of expression of MUM-1/IRF4, CD10, bcl-6, bcl-2 and Ki-67 ( ≥25% )were 39. 8% ( 39/98 ), 62.2% ( 61/98 ), 80. 6% ( 79/98 ), 87. 8% ( 86/98 ) and 50. 0% ( 49/98 ),respectively. MUM-1/IRF4 predominantly expressed in high-grade follicular lymphoma and showed a significantly positive correlation with lymphoma grade ( r = 0. 628, P = 0. 000 ) and Ki-67 index ( r = 0. 473,P = 0.000). MUM-1/IRF4 expression had a significantly negative correlation with CD10 expression (r = -0. 597, P = 0. 000), but no correlation with bcl-6 and bcl-2 expression. Conclusions MUM-1/IRF4 expression is significantly higher in high-grade follicular lymphoma, indicating that these cases have a high proliferative activity, more aggressive behavior and poorer prognosis. MUM-1/IRF4, when strongly expressed, is another helpful marker for the diagnosis of high-grade follicular lymphoma.
